If you missed out of the great #NephJC chat this week you can catch-up with our rapid 10 tweet summary.
This week, we will discuss the origins of primary hyperaldosteronism in normotensive patients. Could this undetected anomaly be the cause of idiopathic hypertension and CKD?
This week, we will discuss the HOPE trial - no not that one - the one in dialysis that was a LBCT in 2024. Should we look beyond analgesics to non-pharmacological options more seriously?
Should we call 2024 the Renaissance of nephrology? It was probably the richest year in RCTs in the nephrology world, reflected in the higher number of Late-Breaking Clinical Trials sessions at every big nephrology congress. Probably 1st place won’t surprise anyone; it was the anticipated FLOW of the year, but this Top 10 Nephrology Stories definitely includes some unexpected titles
This week we come to meta-analyse, strikingly late, the cornerstone of all CKD treatments. Are you still in doubt? We need ACEing CKD to the end of GFR, and beyond
If you missed out of the great #NephJC chat this week you can catch-up with our rapid 10 tweet summary.
Welcome to #TenTweetNephJC
— Nephrology Jrnl Club (@NephJC) August 3, 2022
To salt or not to salt? 🧂 That is the question in heart failure💔
✳️ 10 tweets #NephJC catch-up ✳️
Missed the SODIUM-HF trial discussed last week? Read on for a snapshot of this RCT of dietary sodium reduction in patients with heart failure! pic.twitter.com/mk5D8YAvwF